Halyna Buvailo, PhD

Dr. Halyna Buvailo is a scientist with broad expertise in inorganic chemistry and crystallography, as well as instrumental methods of physico-chemical characterization of chemical substances and materials. She has extensive science writing and editorial experience and currently works as a research analyst for UORSY —a leading supplier of building blocks and screening compounds for drug discovery. She is also affiliated with Kyiv National Taras Shevchenko University of Kyiv, where she obtained her Ph.D. in Chemistry. Halyna is also a certified nutritionist.

Contributing Author in
Clinical Trials Biotech Tools & Methods

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Halyna

Irish AI Startup Focused on Natural Peptide Discovery Secures $42M

Nuritas, an Irish biotech company specializing in AI-powered peptide discovery from natural sources, announced it has raised $42 million in a Series C funding round. The company plans to use the capital to scale operations and expand its global …

Exploring a Novel Approach to Treat Primary Ciliary Dyskinesia: The RCT1100 Study

ReCode Therapeutics, a leader in genetic medicines, is pioneering a promising avenue in the treatment of primary ciliary dyskinesia (PCD) with its latest clinical trial involving RCT1100, a groundbreaking mRNA-based therapy. This novel approach is the first of its kind …

InVivo Biosystems Raises $3M for CRISPR Research and Welcomes New Board Chairman

InVivo Biosystems, operating in the realm of CRISPR-edited animal models for biomedical research, has recently embarked on a new phase of growth and innovation. The Eugene, Oregon-based company has secured a notable $3 million investment, a collaborative effort led by …

SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier® Technology

In a new development in the field of dermatological therapeutics, SiSaf Ltd, a biopharmaceutical company based in Guildford, UK, has reached a pivotal stage for its novel treatment for alopecia areata. The company, renowned for its work in RNA therapeutics …

Collaboration Between Iktos and Curreio Harnesses AI and Cryo-EM for Drug Discovery

Iktos, a French AI-focused company specializing in new drug design, and Curreio, a Japanese cryo-electron microscopy (cryo-EM) expert, have recently entered into a collaboration agreement. The partnership aims to leverage the power of artificial intelligence (AI) and cryo-EM technology to …

AI-Powered Peptide Discovery from Plant Sources Leads to a Breakthrough In Muscle Recovery

Nuritas, an innovator in AI-based peptide discovery from natural sources, has announced the results of a second clinical trial on its patented ingredient, PeptiStrong™. The ingredient, which is sourced from plants and discovered using Nuritas' exclusive AI peptide-discovery platform, has …

Gandeeva Therapeutics and Moderna Join Forces to Explore AI-Enabled Cryo-EM Technology

Gandeeva Therapeutics, a precision medicine company specializing in designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, has announced a new research collaboration with Moderna Inc. The partnership aims to explore the potential applications of …

AI and Cryo-EM: A Powerful Alliance for Unraveling Biological Mysteries

As we delve deeper into the uncharted territories of biotechnology, the convergence of artificial intelligence (AI) and cryo-electron microscopy (Cryo-EM) has emerged as a powerful partnership for unlocking complex biological structures. In this blog post, we'll explore how AI is …